Clinical Trial Detail

NCT ID NCT03193918
Title Study of Crenolanib With Ramucirumab and Paclitaxel for Advanced Esophagogastric Adenocarcinoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Arog Pharmaceuticals, Inc.
Indications

gastric adenocarcinoma

esophagus adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Crenolanib + Paclitaxel + Ramucirumab

Age Groups: adult senior

No variant requirements are available.